The headline reads as positive (94% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The rest of the picture is mixed, so the headline alone is not enough for a clear call.
Stocks › KRYS
Krystal Biotech, Inc. (KRYS) stock analysis
SKIP 11% confidence · analysed Oct 15, 2026
On Oct 15, 2026, our model rated Krystal Biotech, Inc. (KRYS) SKIP with 11% confidence at a price of $330.69. That means the signals cancel out; the model sees no clear edge either way.
SectorHealthcare
IndustryBiotechnology
Market cap9.79B
Analysed price$330.69
Technical picture
The 14-day RSI is 41. Momentum is soft: below the neutral 50 line, but not yet oversold.
MACD is below its signal line, so short-term momentum is pointing down.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is about normal (0.9x the 20-day average).
Trend structure and money flow
Market structure: bullish structure intact, no fresh break.
The most recent swing high is $382.54 and the swing low is $297.02; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The company reports a profit margin of 54.8% and revenue growth of +24.1%.
In its latest quarter it earned $1.79 per share, which missed the $1.91 analysts expected, with revenue +24.1% year over year.
Wall Street's average rating is 1.2 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $392.11.
The next earnings report is expected around Nov 2, 2026; prices often move sharply around earnings.
The model's one-paragraph read
No clear edge (SKIP) — composite score +0.11 (SKIP). Technicals: RSI 40.51, MACD bearish, price below SMA50. Fundamentals: margin 54.8%, revenue growth 24.1%. Financial results: YoY revenue +24.1%, last EPS surprise -6.3%, next earnings 2026-11-02. Smart Money Concepts: bullish structure intact, no fresh break, price retesting a bullish order block, price retesting a bearish order block, sitting inside an unfilled bearish fair value gap. FinGPT news read: positive. Memory: 1 prior look(s). Reference price $334.31; no trade levels (SKIP).
Past ratings for KRYS
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 15, 2026 | SKIP | 11% | $330.69 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on KRYS
Oct 15, 2026 · Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
- Oct 15, 2026: Krystal Biotech Reports KB113 Lesion Regression in Gorlin Syndrome Pilot Study as FDA Discussions Begin (InvestorsHub)
- Oct 15, 2026: Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome (GlobeNewswire)
Other Healthcare stocks we cover
LEGN · LH · LLY · LQDA · MDT · NRC · NVO · OSCR · PCRX · PFE · PGNY · PHG
Frequently asked questions
Is KRYS a buy right now?
As of Oct 15, 2026, our automated model rates Krystal Biotech, Inc. (KRYS) SKIP with 11% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
When does Krystal Biotech, Inc. report earnings next?
The next earnings report is expected around Nov 2, 2026.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.